Literature DB >> 6199399

Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells.

D A Fields, J Pillar, W Diamantis, J L Perhach, R D Sofia, N Chand.   

Abstract

The ability of azelastine and selected antiallergic drugs to inhibit compound 48/80-induced and PS-potentiated, Con A-induced histamine release from RPMC was investigated. Azelastine, ketotifen, theophylline, and DSCG added simultaneously with the secretagogues or preincubated with the RPMC for 10 min before the addition of secretagogues produced concentration-dependent inhibition of histamine release. In general, the relative order of potency at calculated IC50 level was as follows: azelastine greater than ketotifen greater than theophylline greater than DSCG. The preincubation of RPMC with azelastine for 10 min exerted 3.5 times greater inhibition of Con A plus PS-stimulated histamine release but did not influence the inhibitory activity on compound 48/80-induced release. The duration of preincubation did not influence the inhibitory effects of ketotifen with either secretagogue. Theophylline and DSCG exerted significantly greater inhibition when they were added simultaneously with Con A plus PS. The inhibitory activity of DSCG was also significantly improved upon simultaneous addition with compound 48/80. These data demonstrated that azelastine is the most potent inhibitor of nonallergic histamine release from RPMC among the four antiallergic drugs examined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199399     DOI: 10.1016/0091-6749(84)90415-9

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness.

Authors:  C A Gould; S Ollier; R Aurich; R J Davies
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

2.  The effect of azelastine and some other antiasthmatic and antiallergic drugs on calmodulin and protein kinase C.

Authors:  E Middleton; P Ferriola; G Drzewiecki; R D Sofia
Journal:  Agents Actions       Date:  1989-08

Review 3.  Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 4.  Heterogeneity of calcium channels in mast cells and basophils and the possible relevance to pathophysiology of lung diseases: a review.

Authors:  N Chand; J L Perhach; W Diamantis; R D Sofia
Journal:  Agents Actions       Date:  1986-03

5.  Modulation of in vitro anaphylaxis of guinea-pig isolated tracheal segments by azelastine, inhibitors of arachidonic acid metabolism and selected antiallergic drugs.

Authors:  N Chand; W Diamantis; R D Sofia
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

Review 6.  The antihistamines of the nineties.

Authors:  M M Janssens; P H Howarth
Journal:  Clin Rev Allergy       Date:  1993

7.  Azelastine inhibits stimulated histamine release from human lung tissue in vitro but does not alter cyclic nucleotide content.

Authors:  M M Little; D R Wood; T B Casale
Journal:  Agents Actions       Date:  1989-08

8.  Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs.

Authors:  N Chand; J Pillar; W Diamantis; R D Sofia
Journal:  Agents Actions       Date:  1985-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.